Form 4: Maze Therapeutics CEO Sells Shares Under 10b5-1 Plan

Maze Therapeutics CEO Jason V. Coloma has sold a significant number of company shares, totaling over 25,000, through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jason V. Coloma, CEO of Maze Therapeutics, Inc., reported transactions involving the sale of common stock on June 22 and June 23, 2026.
• These sales were executed under a Rule 10b5-1 trading plan adopted on February 6, 2026, which is designed to comply with affirmative defense conditions.
• A total of 1,953 shares were sold on June 22, 2026, at a weighted average price of $26.00 per share.
• An additional 23,865 shares were sold on June 23, 2026, at a weighted average price of $26.0496 per share.
• Following these transactions, Mr. Coloma's beneficial ownership of Maze Therapeutics common stock has been adjusted.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transactions were conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned divestiture rather than a reaction to negative company news.

Negatives

• CEO Jason V. Coloma sold a total of 25,818 shares of Maze Therapeutics common stock.
• The sales occurred on June 22 and June 23, 2026, at weighted average prices of $26.00 and $26.0496 respectively.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding future company performance.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common for executives seeking to diversify holdings or manage personal finances, and are generally not viewed negatively if executed according to a pre-established plan.

Stakeholder Impact

• Shareholders may observe the sale of shares by the CEO, but the execution under a Rule 10b5-1 plan suggests it is a pre-planned event and not necessarily a reflection of negative company outlook.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Maze Therapeutics, Jason V. Coloma, Stock Sale, Beneficial Ownership